In a showdown with Sanofi, FDA questions Novo's PhIII data for IDegLira | Fierce Biotech
Mixed reaction to Novo Nordisk obesity trial - PMLiVE
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
Physicians' real-world experience with IDegLira: results of a European survey | BMJ Open Diabetes Research & Care
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy
IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUAL V - Media Centre | EASD
Overview of studies design evaluating the efficacy of iDegLira and... | Download Scientific Diagram
Insulin Degludec Insulin Aspart (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Liraglutide Insulin Degludec Ideglira Xultophy (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes - ScienceDirect
Dosificación, Titulación y Aplicación de iDegLira - Novo Nordisk
Switching to a fixed-ratio combination of insulin degludec/liraglutide ( IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the
Novo Nordisk invests $60 million in expansion of Kalundborg site
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in
Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population - Liu - 2022 - Journal of Diabetes Investigation - Wiley Online Library
Presentan en México IDeglira para tratar la diabetes tipo 2 – Mundodehoy.com
Novo Nordisk's GLP-1/insulin combination, Xultophy, Moves One Step Closer to Approval in Europe
Frontiers | Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting
Novo posts strong performance, but US pricing pressure grows | pharmaphorum
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
Novo Nordisk and Sanofi diabetes combo drugs receive US recommendation
Summary of the effects of iDegLira and iGlarLixi on postprandial... | Download Scientific Diagram
REMIT-iDegLira - Research Studies - PHRI - Population Health Research Institute of Canada
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients
